J&J Pushes Back Launch Of Ottava Robotic Platform By Two Years
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.
You may also be interested in...
News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Minute Insight: Medtronic Brings Hugo RAS To Canada
Health Canada has licensed Hugo for urologic and gynecologic laparoscopic surgical procedures.